Placebos
Transcend’s neuroplastogen posts positive mid-stage results in PTSD
TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect
AlgoTx’s ATX01 Shows Promise Despite Missing Primary Endpoint in Phase 2 CIPN Trial
AlgoTx, ATX01, chemotherapy-induced peripheral neuropathy (CIPN), Phase 2 trial, placebo effect, non-opioid pain relief, topical amitriptyline
Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism
Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect
Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal
Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance